Mark Spellman, Co-Portfolio Manager at Alpine Funds, talks about some of the companies that have recently raised their dividends. » Read More
David Pearl of Epoch Investment Partners and David Moon of Moon Capital Management offered CNBC their insights. (Part 2: Personal Products)
Here's the Thursday edition of the Fast Money Final Trade. The crew presents tomorrow's best trades, right now!
The pitter-patter of little feet and the high-pitched cries of infants may seem louder lately, but it's music to the ears of many companies that cater to infants and children.
Stocks advanced Tuesday, building on the prior session's rally, as a drop in oil prices and encouraging outlook from Cisco helped offset disappointment in Freddie Mac's results.
With the Olympics about to begin, some multinationals are betting big with over $800 million in sponsorship rights. Does the big investment in advertising payoff?
Here's our Fast Money Final Trade. Tomorrow's best trades, right now!
Health care stocks have been the stealth performers, and they will likely continue to outperform because of steady earnings, a favorable macro environment and cheap valuations, says Merrill Lynch's Brian Belski.
Cramer makes the call on viewers' favorite stocks.
Mat DiFilippo, senior portfolio manager at Stewart Capital and Randy Lert, chief portfolio strategist at Russell Investments offered advice on different sectors that could help benefit investors.
Bruce Levis, managing director at McQueen, Ball & Associates, says that the market has yet to hit bottom, but offered a few sector selections that could benefit investors.
So Exxon Mobil has just broken its own record again, reporting a mind-boggling $11.6 billion profit on $138 billion in sales. Windfall? Nope: Microsoft is three times more profitable than Exxon.
The Dow tumbled on Monday as more credit and housing market turmoil battered financial shares.
In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
To help investors prepare their portfolios before the weekend, CNBC asked the experts for their best trades now.
Symmetry Medical proves investors can speculate and play defense at the same time.
In Thursday’s Web Extra the traders talk China – now growing at its slowest pace since 2005. Also Pete Najarian has more fun with Pharma.
In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.
The Dow rallied on Wednesday after strong results from Wells Fargo lifted the entire banking sector to it’s biggest one day gain in almost two decades. What's the "Word on the Street?"